Cargando…

ADAR and hnRNPC deficiency synergize in activating endogenous dsRNA-induced type I IFN responses

Cytosolic double-stranded RNA (dsRNA) initiates type I IFN responses. Endogenous retroelements, notably Alu elements, constitute a source of dsRNA. Adenosine-to-inosine (A-to-I) editing by ADAR induces mismatches in dsRNA and prevents recognition by MDA5 and autoinflammation. To identify additional...

Descripción completa

Detalles Bibliográficos
Autores principales: Herzner, Anna-Maria, Khan, Zia, Van Nostrand, Eric L., Chan, Sara, Cuellar, Trinna, Chen, Ronald, Pechuan-Jorge, Ximo, Komuves, Laszlo, Solon, Margaret, Modrusan, Zora, Haley, Benjamin, Yeo, Gene W., Behrens, Timothy W., Albert, Matthew L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313407/
https://www.ncbi.nlm.nih.gov/pubmed/34297039
http://dx.doi.org/10.1084/jem.20201833
Descripción
Sumario:Cytosolic double-stranded RNA (dsRNA) initiates type I IFN responses. Endogenous retroelements, notably Alu elements, constitute a source of dsRNA. Adenosine-to-inosine (A-to-I) editing by ADAR induces mismatches in dsRNA and prevents recognition by MDA5 and autoinflammation. To identify additional endogenous dsRNA checkpoints, we conducted a candidate screen in THP-1 monocytes and found that hnRNPC and ADAR deficiency resulted in synergistic induction of MDA5-dependent IFN responses. RNA-seq analysis demonstrated dysregulation of Alu-containing introns in hnRNPC-deficient cells via utilization of unmasked cryptic splice sites, including introns containing ADAR-dependent A-to-I editing clusters. These putative MDA5 ligands showed reduced editing in the absence of ADAR, providing a plausible mechanism for the combined effects of hnRNPC and ADAR. This study contributes to our understanding of the control of repetitive element–induced autoinflammation and suggests that patients with hnRNPC-mutated tumors might maximally benefit from ADAR inhibition-based immunotherapy.